How big is RxSight, Inc.?

As of Jun 18, RxSight, Inc. has a market capitalization of 548.60 million, with net sales of 148.31 million and a net profit of -26.55 million for the latest four quarters. As of Dec 24, shareholder's funds are 281.24 million, and total assets are 321.42 million.

As of Jun 18, RxSight, Inc. has a market capitalization of 548.60 million, categorizing it as a Small Cap company.<BR><BR>As of Jun 24, the sum of net sales for the latest four quarters is 148.31 million, while the sum of net profit for the same period is -26.55 million.<BR><BR>As of Dec 24, the shareholder's funds amount to 281.24 million, and total assets are reported at 321.42 million.

What does RxSight, Inc. do?

RxSight, Inc. is a small-cap company in the Electronics & Appliances industry, reporting net sales of $38 million and a net loss of $8 million as of March 2025, with a market cap of $548.60 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -9.50%.

Overview:<BR>RxSight, Inc. operates within the Electronics & Appliances industry and is classified as a small-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 38 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -8 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 548.60 Million (Small Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.82 <BR>Return on Equity: -9.50% <BR>Price to Book: 1.96<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Should I buy, sell or hold RxSight, Inc.?

Is RxSight, Inc. overvalued or undervalued?

As of November 10, 2021, RxSight, Inc. is considered a risky investment due to its overvaluation and poor financial metrics, including a Price to Book Value of 2.19 and a year-to-date stock return of -72.4%, significantly underperforming the S&P 500.

As of 10 November 2021, the valuation grade for RxSight, Inc. has moved from does not qualify to risky, indicating a deterioration in its investment profile. The company appears to be overvalued given its negative financial metrics, including a Price to Book Value of 2.19, an EV to Sales ratio of 2.58, and an EV to EBITDA of -11.40. Comparatively, Methode Electronics, Inc. has a more favorable EV to EBITDA of 13.0540, highlighting RxSight's relative weakness in valuation.<BR><BR>The company’s recent stock performance has been poor, with a year-to-date return of -72.4% compared to the S&P 500's positive return of 12.22%. This stark contrast reinforces the notion that RxSight, Inc. is currently overvalued in the market.

Is RxSight, Inc. technically bullish or bearish?

As of September 5, 2025, RxSight, Inc. shows a mildly bearish technical trend with mixed indicators, underperforming the S&P 500 significantly with year-to-date returns of -72.4% compared to 12.22%.

As of 5 September 2025, the technical trend for RxSight, Inc. has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The Bollinger Bands and moving averages are both showing mildly bearish signals on the weekly and daily time frames. The KST is mildly bullish weekly but bearish monthly, and the Dow Theory indicates no trend on the weekly but mildly bearish on the monthly. <BR><BR>In terms of performance, RxSight has underperformed significantly compared to the S&P 500, with a year-to-date return of -72.4% versus the S&P 500's 12.22%, and a one-year return of -82.48% compared to 17.14%. Overall, the current technical stance is mildly bearish, driven by mixed signals across various indicators.